Two markets. One platform. Multiple paths to scale.
Operating at the intersection of clinical liquid biopsy and BioPharma companion services — each projected to exceed $10B this decade. A single technology generating value across both.
Market figures based on third-party research for global liquid biopsy and companion diagnostics sectors. Shown for directional illustration.
Liquid Biopsy
Addressable segments span mammogram triage (BI-RADS 4), MRD and recurrence monitoring, and early-stage cancer screening — across US and global health systems.
- ~1.5M breast biopsies annually in the US, ~80% benign
- Multi-thousand-dollar cost per avoided biopsy
- MRD and recurrence monitoring growing at 25%+ CAGR
Trial & CDx Support
Partnerships across trial enrichment, patient stratification, resistance profiling, and companion diagnostic co-development with oncology pharma.
- Hundreds of active oncology trials needing biomarker enrichment
- Significant per-patient trial savings via responder pre-screening
- Milestone + royalty revenue models in CDx partnerships
"A single platform generating clinical diagnostics revenue and BioPharma partnership payments — multiple paths to commercialization along the oncology value chain."
Where the Platform Creates Value
Six high-value clinical needs across the cancer continuum — each addressable by the same core capability: single-molecule precision, ultra-low input, and a multi-dimensional readout that today's tools cannot match.
Mammogram Triage
Risk-stratify BI-RADS 4 patients before biopsy. Spare benign cases the procedure; prioritize the rest for intervention.
~1.5M biopsies/year (US)MRD & Recurrence
Detect residual or returning disease at tumor fractions below the ctDNA detection floor — enabling earlier intervention in post-treatment surveillance.
25%+ CAGR segmentEarly Cancer Screening
Blood-based screening with preserved sensitivity at the earliest stages — closing the compliance and detection gaps left by stool and cfDNA tests.
Growing global demandTrial Enrichment
Pre-screen trial candidates using regulatory-marker signatures. Reduce screen failure, accelerate enrollment, improve outcomes.
500+ oncology trialsPatient Stratification
Multi-parametric signatures for nuanced cohort selection in basket and precision oncology trials — beyond single-gene biomarkers.
Growing demandCompanion Diagnostics
Co-developed IVDs with pharma partners — milestone-and-royalty structures, full lifecycle support from trial through launch.
$8B+ CDx marketWant to Dig Deeper?
We welcome conversations with investors evaluating the liquid biopsy space and pharma partners exploring next-generation biomarker tools.